Therefore, PGE2 or COX2 expression should be considered in a specific tumor background to determine the therapeutic schedule and whether COX2 inhibitors can be used to enhance the cancer immunotherapeutic effect of type I IFNs alone or in combination with ICBs needs to be further investigated. Here, PTGS2 is linked to cancer.